{"name":"Paratek Pharmaceuticals","slug":"paratek","ticker":"PRTK","exchange":"NASDAQ","domain":"paratekpharma.com","description":"Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative anti-infective therapies. The company's lead product, Nuzyra (omadacycline), is a broad-spectrum antibiotic approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek's pipeline also includes Sotrovimab, a monoclonal antibody for the treatment of COVID-19. The company is positioned to capitalize on the growing demand for anti-infective therapies.","hq":"Boston, MA","founded":2011,"employees":"","ceo":"Evan Loh","sector":"Anti-Infectives / Specialty Pharma","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"0","metrics":{"revenue":95000000,"revenueGrowth":-2983,"grossMargin":0,"rdSpend":0,"netIncome":-63566000,"cash":172538000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Nuzyra patent cliff ($0.0B at risk)","drug":"Nuzyra","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Paratek Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with revenue of $13.4 million and a net loss of $43.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Paratek Pharmaceuticals Announces Collaboration with the Bill and Melinda Gates Foundation to Develop New Antibiotic Therapies","summary":"Paratek Pharmaceuticals announced a collaboration with the Bill and Melinda Gates Foundation to develop new antibiotic therapies for the treatment of bacterial infections in low- and middle-income countries.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves Sotrovimab for the Treatment of COVID-19","summary":"The FDA approved Sotrovimab, a monoclonal antibody developed by Paratek Pharmaceuticals, for the treatment of COVID-19 in adults and pediatric patients.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5xRzRUUnVRTzROYmtwdVlXUUxIblROYURHZ3JDRFR1TEszUjhMc0Q3RnExdncwY3FuWHpwRDlTMTdSRFFUbnpmU3dyMUJ0XzVjTVRZ?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"PRTK Stock Price, News & Analysis - Stock Titan","headline":"PRTK Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPVElRZWZsUEZGcE5DcmRYOWpoQThObDRYYUhyRUhiaTZZU3pXZHJkYzJzSXc0TzFnZFFFa2FxMjVfSFNpTmpVdlNrNjA5RTlpdV9fd2hQQ3NKQmpxcjhIYmx3dGhTMTVfMzRCUlRKeERMRUJsMTNZSDRYNkMxc3BWMy1BUUEydEJ1US13b1Fn?oc=5","date":"2023-09-19","type":"pipeline","source":"Yahoo Finance","summary":"Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the company - Yahoo Finance","headline":"Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPQ0pSbXZzeDFId3BlM0JwWUFRcXlwdG83bXhGRmFVTFpDbjZST3ZvMkFNSHFLbDUtemFFTklfaW1vOTlPVHJVdGJPZEY0VDlvRDUtQ2ZxS2N1ZVpvTUs4WEQtUi1OMmg0YjJjWWtVWGJ0RjlsQmpVZHY4cGxic05JMDRsbExldjl6MGdrOHhHNE1CaThvRW1hRVVHdExBWnQtTXJIdEM3NllCeUM4cmc?oc=5","date":"2023-06-06","type":"deal","source":"Novo Holdings","summary":"Paratek Pharmaceuticals to be Acquired by Gurnet Point Capit - Novo Holdings","headline":"Paratek Pharmaceuticals to be Acquired by Gurnet Point Capit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNRjJSNUphM0E0MVR3NVd0Z1NtdEtHZmtUTUYyQ01YRmJ5dkZyTXdNVkxPb2ktdUxMckhfcWl3MDhuU1pKeFM1YTlWbjZobEdzZS1WY1lfczEyY2JKMWZGQXVOOENwQjgxdjBYbVNKeEpHSkZYbjVfWS1sbUNMeVFMcDZLNnI5a0R1b3dNZVVxTHU1UEVhYTF5cmVoRDhrdTNlZnlwMEVEN0pRc0tDdFBYWTlHQWpMQQ?oc=5","date":"2023-06-06","type":"deal","source":"Fierce Pharma","summary":"Novo Holdings, Gurnet Point team up to buy antibiotics maker Paratek for $462M - Fierce Pharma","headline":"Novo Holdings, Gurnet Point team up to buy antibiotics maker Paratek for $462M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9pc3ZxWUdaY1JRYkowRDlLQXk2aFRyNjhPUS1CTUlwQjZWaDNWVFhFT09UT1oyYVliTHBvbm1rUC1EOFBfWGlLYVBKYndTSWl0QlhHeXlHbUlkb2N0SU5j?oc=5","date":"2019-11-17","type":"pipeline","source":"ChartMill","summary":"PRTK Stock Price, Quote & Chart | PARATEK PHARMACEUTICALS INC (NASDAQ:PRTK) - ChartMill","headline":"PRTK Stock Price, Quote & Chart | PARATEK PHARMACEUTICALS INC (NASDAQ:PRTK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOdGhmbWFMQUc3TU5mWkdIZ0h3dU5qNDlhRXF3Tk5Gemw0QUw2Qjh4TTZXWkNRMmhJSzYyU3Z0enlGMktjQlR3RGpKSFBsZFpXcG1MdEZZZFFoSGRhd0RaTHRwWGNUWVpnQlRUZmdWeUNVVXVpcGtPV3Z4SWtpNzVnVGE5NkdaQUMxV1E?oc=5","date":"2018-02-15","type":"regulatory","source":"MassDevice","summary":"After 20 years, Paratek’s broad-spectrum antibiotic is headed to the FDA - MassDevice","headline":"After 20 years, Paratek’s broad-spectrum antibiotic is headed to the FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQYlEtOVkySkRoemM3UjZkNElMQnlhalNkWTZTOGlFQ1M3empoLWtIdDdJbHpndGd2YnVXTTRhYmtjd2Zaa0tJQmxkeHRxU3RPME1DVlFKVkd3Y1ZNdTh6X0JPY2dfcTJtR2dEQkFwZnFiLVo4Y0RNMUdXX0g5NWxBTzF0ZUtxT2FFUFNOZzEwYVJ0eGJjc2o4?oc=5","date":"2018-02-15","type":"regulatory","source":"Drug Delivery Business","summary":"After 20 years, Paratek’s broad-spectrum antibiotic is headed to the FDA - Drug Delivery Business","headline":"After 20 years, Paratek’s broad-spectrum antibiotic is headed to the FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxONkIxTXdqNlNQN21kdngyQ0lBN2hqMTdDR01sTWVJMnVLa1Q5UW5XcGMzZTFZV0dnWWMyM0plb1VMUWVlem1UMUZ5Nm0yTEJSalNRNGR4dDhRXzN2emFoQWU5RDNQay10MmNram1YX2FlblY0Q0RHYU1taFlTV1FVU25odmtWUHE5S3daQ0l6ZGRzenJwU29LcDhPYzBPbFlpNFRmMjBBa01hQVk?oc=5","date":"2018-01-17","type":"pipeline","source":"RTTNews","summary":"Paratek Pharmaceuticals Inc. (PRTK) Is Losing Ground On Offering News - RTTNews","headline":"Paratek Pharmaceuticals Inc. (PRTK) Is Losing Ground On Offering News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPZ05QT2l1ZXRPWHgtMzFPNVNxM0JwU08tN1JabDgyXzVERkp1M00tVjZKanpUMG1LREQ0amJuRnA4ZGpGU2hFNmNVV3VIUXRhNzBhOVJvZDdXcXVjVk1idGR1alVQZThXcEpIVU13Z0VnQmVzSjhEejJqNTNzeXpOZV9wYjRubUQ4U1U4b3Y4TG1VcXNHYXZUZ0lrWEk0SEpKc0tRSlhEWE1iN09oTDh5MTZSUy1PTkJKR1RRR1VoV3BDMjI4WGpTV1lvTlVoVlQ5dTM4TUF0U3BqV2FEUzhLNk9xc3p5LVNoT281M1VB?oc=5","date":"2017-12-20","type":"regulatory","source":"PR Newswire","summary":"FDA Accepts New Drug Application For Seysara™ (Sarecycline) For The Treatment Of Moderate To Severe Acne - PR Newswire","headline":"FDA Accepts New Drug Application For Seysara™ (Sarecycline) For The Treatment Of Moderate To Severe Acne","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQdVZ3WTRIdHhnV2dDZ21MWERVckY5S25XQW9XSWVYM0JHb3hib1F5SGs5REhKcXRUSFdMTkpmMjFYTllPbEItbDZSR0l1LXJ2d3dqYzlWR3RLSE9QQURPbUJpNmxwclU5cjdwWXJyNUhqS1UwajhBMTFDclYzMUV4U0FaN3I3ZmhHU2gtZ2dMTWJYVE0?oc=5","date":"2017-04-04","type":"pipeline","source":"The Motley Fool","summary":"Why Paratek Pharmaceuticals Inc Is Soaring - The Motley Fool","headline":"Why Paratek Pharmaceuticals Inc Is Soaring","sentiment":"neutral"}],"patents":[{"drugName":"Nuzyra","drugSlug":"omadacycline","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Merck & Co.","Pfizer Inc.","Gilead Sciences Inc."],"therapeuticFocus":["Anti-infectives","Specialty pharma"],"financials":{"source":"sec_edgar+yahoo","revenue":-5074000,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":-5074000,"period":"2013-12-31"},{"value":176000,"period":"2013-12-31"},{"value":382000,"period":"2013-09-30"},{"value":198000,"period":"2013-06-30"},{"value":-5830000,"period":"2013-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-63566000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":172538000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}